Iconovo AB (publ) (ICO.ST)
SEK 4.17
(-2.11%)
SEK 4.17
(-2.11%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 63.35 Million SEK | -3.43% |
| 2022 | 65.6 Million SEK | 37.23% |
| 2021 | 47.8 Million SEK | 28.16% |
| 2020 | 37.3 Million SEK | 47.78% |
| 2019 | 25.24 Million SEK | 42.14% |
| 2018 | 17.75 Million SEK | 3.23% |
| 2017 | 17.2 Million SEK | 34.45% |
| 2016 | 12.79 Million SEK | 639750100.0% |
| 2015 | -2.00 SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 14.37 Million SEK | -2.36% |
| 2024 Q1 | 15.11 Million SEK | 4.14% |
| 2024 Q2 | 14.71 Million SEK | -2.62% |
| 2023 FY | 63.35 Million SEK | -3.43% |
| 2023 Q4 | 14.51 Million SEK | 0.56% |
| 2023 Q3 | 14.43 Million SEK | -20.89% |
| 2023 Q2 | 18.24 Million SEK | 12.85% |
| 2023 Q1 | 16.16 Million SEK | -19.25% |
| 2022 Q2 | 17.22 Million SEK | 13.94% |
| 2022 FY | 65.6 Million SEK | 37.23% |
| 2022 Q4 | 20.01 Million SEK | 51.08% |
| 2022 Q3 | 13.25 Million SEK | -23.06% |
| 2022 Q1 | 15.11 Million SEK | 10.61% |
| 2021 FY | 47.8 Million SEK | 28.16% |
| 2021 Q3 | 10.18 Million SEK | -15.95% |
| 2021 Q2 | 12.11 Million SEK | 2.33% |
| 2021 Q4 | 13.66 Million SEK | 34.19% |
| 2021 Q1 | 11.84 Million SEK | 5.3% |
| 2020 Q4 | 11.24 Million SEK | 29.74% |
| 2020 Q3 | 8.66 Million SEK | -6.46% |
| 2020 Q2 | 9.26 Million SEK | 14.1% |
| 2020 FY | 37.3 Million SEK | 47.78% |
| 2020 Q1 | 8.12 Million SEK | 48.9% |
| 2019 Q4 | 5.45 Million SEK | -15.17% |
| 2019 Q3 | 6.42 Million SEK | -7.3% |
| 2019 Q2 | 6.93 Million SEK | 7.94% |
| 2019 Q1 | 6.42 Million SEK | 26.42% |
| 2019 FY | 25.24 Million SEK | 42.14% |
| 2018 Q4 | 5.08 Million SEK | 36.4% |
| 2018 Q2 | 4.67 Million SEK | 9.41% |
| 2018 Q1 | 4.27 Million SEK | -23.06% |
| 2018 FY | 17.75 Million SEK | 3.23% |
| 2018 Q3 | 3.72 Million SEK | -20.32% |
| 2017 Q4 | 5.55 Million SEK | 96.43% |
| 2017 Q3 | 2.82 Million SEK | -57.59% |
| 2017 Q2 | 6.66 Million SEK | 209.9% |
| 2017 FY | 17.2 Million SEK | 34.45% |
| 2017 Q1 | 2.15 Million SEK | 0.0% |
| 2016 FY | 12.79 Million SEK | 639750100.0% |
| 2015 FY | -2.00 SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 23.531% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 89.645% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 89.645% |
| Arcoma AB | 53.25 Million SEK | -18.971% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -1174.993% |
| BICO Group AB (publ) | 2.84 Billion SEK | 97.776% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 69.895% |
| CellaVision AB (publ) | 295.99 Million SEK | 78.596% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | 8.089% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -4739.233% |
| C-Rad AB (publ) | 3.8 Million SEK | -1567.222% |
| Duearity AB (publ) | 21.58 Million SEK | -193.511% |
| Dignitana AB (publ) | 74.73 Million SEK | 15.229% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -2246.46% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.411% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -247.556% |
| Integrum AB (publ) | 90.57 Million SEK | 30.05% |
| Luxbright AB (publ) | 23.09 Million SEK | -174.374% |
| Mentice AB (publ) | 237.06 Million SEK | 73.275% |
| OssDsign AB (publ) | 175.6 Million SEK | 63.921% |
| Paxman AB (publ) | 133.8 Million SEK | 52.65% |
| Promimic AB (publ) | 48.55 Million SEK | -30.488% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 60.985% |
| SciBase Holding AB (publ) | 69.97 Million SEK | 9.463% |
| ScandiDos AB (publ) | 61.03 Million SEK | -3.795% |
| Sectra AB (publ) | 39.06 Million SEK | -62.185% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 63.7% |
| Senzime AB (publ) | 141.51 Million SEK | 55.232% |
| SpectraCure AB (publ) | 12.12 Million SEK | -422.381% |
| Stille AB | 87.21 Million SEK | 27.362% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 98.862% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 85.631% |